ADA Scientific Sessions 2026 Abstract

Socioeconomic Differences in Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors among Eligible U.S. Adults with Type 2 Diabetes

By Yu N. Wang, Kai Bullard, Rui Li, Osatohamwen Idubor, Ping Zhang

Study in peoplePopulations

The paper

Yu N. Wang, Kai Bullard, Rui Li, Osatohamwen Idubor, Ping Zhang

Cham

ADA Scientific Sessions 2026 Abstract, 5 Jun 2026

Presented at ADA Scientific Sessions 2026, poster 1969-P

doi.org/10.2337/db26-1969-p

Clinical Journal of the American Society of Nephrology4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Diabetes & Vascular Disease Research4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Diabetes, Obesity & Metabolism8 Oct 2026
Diabetes drug class linked to slightly less frailty progression